Skip to main content
DNTH
NASDAQ Life Sciences

Dianthus Reports Strong 75% Response Rate in Claseprubart Phase 3 CIDP Interim Analysis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$76.45
Mkt Cap
$4.179B
52W Low
$16.635
52W High
$96.503
52W Position info
360% above low
Off High info
21% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

DNTH has more than doubled off its 52-week low of $16.635.

Summary

Dianthus Therapeutics announced positive interim data from Part A of its Phase 3 CAPTIVATE trial for claseprubart in CIDP, showing a 75% response rate and leading to a streamlined Part B trial design.


Key Events · Product Development and Regulatory · DNTH

  • Strong Interim Phase 3 Data

    75% of the first 40 patients in Part A of the CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) achieved a confirmed response.

  • Clinically Meaningful Improvements

    Confirmed responders showed significant improvements across multiple efficacy measures, including INCAT, Grip Strength, MRC-SS, and I-RODS, compared to non-responders.

  • Streamlined Trial Design

    The Phase 3 CAPTIVATE trial's Part B will now enroll fewer patients (128 down from 192) with a 1:1 randomization, reflecting a higher conservative minimum responder rate of 50%.

  • Favorable Safety Profile

    Claseprubart was generally well tolerated with no related serious infections, clinical symptoms of autoimmune activation or Drug-Induced Lupus (DIL), or discontinuations due to safety.


Analysis · DNTH · Life Sciences

This 8-K provides crucial new clinical data supporting the previously announced "GO decision" for the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The 75% response rate from the interim analysis is a strong positive signal for the lead candidate, demonstrating significant efficacy and a favorable safety profile. The subsequent reduction in patient enrollment for Part B indicates increased confidence in the drug's performance and could accelerate the trial's completion, potentially bringing the drug to market faster. This de-risks a key pipeline asset and could significantly impact the company's valuation.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DNTH was trading at $76.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $16.64 to $96.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DNTH - Latest Insights

DNTH
Nov 04, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $85.81
Real-time Price: $86.95 info
Change: +$1.14 (+1%) info
Market Cap: $4.898B info
DNTH
Nov 04, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $85.81
Real-time Price: $86.95 info
Change: +$1.14 (+1%) info
Market Cap: $4.898B info
DNTH
Aug 07, 2026, 6:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $108.92
Real-time Price: $86.95 info
Change: -$21.97 (-20%) info
Market Cap: $4.898B info
DNTH
Aug 07, 2026, 4:18 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.92
Real-time Price: $86.95 info
Change: -$21.97 (-20%) info
Market Cap: $4.898B info
DNTH
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $86.95 info
Change: -$24.05 (-22%) info
Market Cap: $4.898B info